

Daily evidence digest

11 April 2022

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

Budenoside, differences between Omicron and Delta infections, thromboembolism and bleeding after COVID-19

Peer reviewed journals featured:

- A randomised clinical trial on budenoside's effect on the nasal mucosal inflammatory response [here](#)
- Observational studies on:
 - Symptom prevalence, duration, and risk of hospital admission in SARS-CoV-2 infected people during Omicron and Delta variant dominance [here](#)
 - Risks of deep vein thrombosis, pulmonary embolism, and bleeding after COVID-19 [here](#) associated editorial [here](#) and backgrounder on self-controlled case study designs [here](#)
 - The determinants of COVID-19 morbidity and mortality across countries [here](#)
- Commentary on:
 - UK ministers abandon any pretence of “following the science” on COVID-19 [here](#)
 - How T cells defend against COVID-19 [here](#)

Pre-peer review articles featured:

- Antibody resistance of Omicron BA.1, BA.1.1, BA.2 and BA.3 sub-lineages [here](#)
- Delta-Omicron recombinant in a transplant patient treated with sotrovimab [here](#)

Guidance and reports

- The Australian Technical Advisory Group Immunisation (ATAGI) advice on use of sedation for COVID-19 vaccination [here](#)
- The TGA released a statement on receiving an application for an increased dose of sotrovimab (XEVDY) for the BA.2 Omicron sublineage [here](#)
- Updated BMJ best practice guide on COVID-19 outlining update to official list of symptoms [here](#)

News and blogs

- The WHO suspends supplies of India's Covaxin through UN agencies [here](#)
- Infections in England reached record high in March [here](#)

[Click here](#) to subscribe to the daily evidence digest.

Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on SARS-CoV-2 [vaccines](#), and [variants](#) of concern, [post-acute sequelae of COVID-19 \(PASC\)](#), [surgery and COVID-19](#), [rapid testing](#) and [risk mitigation strategies](#).